董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark Strobeck | 男 | Chairman of the Board | 54 | 5.62万美元 | 未持股 | 2025-07-29 |
| Jed A. Latkin | -- | Director, President and Chief Executive Officer | -- | 6.90万美元 | 未持股 | 2025-07-29 |
| Saundra Pelletier | -- | Independent Director | -- | 2.34万美元 | 未持股 | 2025-07-29 |
| Andrew Kucharchuk | 男 | Director | 44 | 未披露 | 未持股 | 2025-07-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steven G. Simonson | 男 | Senior Vice President and Chief Medical Officer | 66 | 46.85万美元 | 未持股 | 2025-07-29 |
| Eric Curtis | 男 | Senior Vice President and Chief Operating Officer | 57 | 41.15万美元 | 未持股 | 2025-07-29 |
| Jed A. Latkin | -- | Director, President and Chief Executive Officer | -- | 6.90万美元 | 未持股 | 2025-07-29 |
董事简历
中英对照 | 中文 | 英文- Mark Strobeck
-
Mark Strobeck自2023年6月起担任Windtree Therapeutics, Inc.董事会成员，并担任审计和薪酬委员会成员。自2022年7月起，斯特罗贝克博士还担任生物制药公司Rockwell Medical, Inc.的总裁兼首席执行官和董事会成员。斯特罗贝克博士曾于2021年5月至2022年6月担任生命科学投资银行Aquilo Partners，LP的董事总经理。他曾于2020年5月至2020年12月担任制药公司Assertio Holdings, Inc.执行副总裁兼首席运营官。在此之前，斯特罗贝克博士于2015年9月与Assertio Holdings公司于2020年5月合并后担任制药公司Zyla Life Sciences的执行副总裁兼首席运营官，并曾于2014年1月至2015年9月担任Zyla的首席商务官。在受雇于Zyla之前，他曾在2012年6月至2013年12月期间担任Zyla的顾问。2012年1月至2013年12月，他担任Corridor Pharmaceuticals，Inc.的总裁兼首席执行官和董事。Corridor Pharmaceuticals，Inc.是一家制药公司，于2014年被阿斯利康收购。2010年12月至2011年10月，斯特罗贝克博士担任Topaz Pharmaceuticals Inc.的首席商务官，这是一家专业制药公司，于2011年第四季度被赛诺菲巴斯德收购。2010年6月至2010年11月和2011年10月至2012年1月，斯特罗贝克博士担任顾问。2008年1月至2010年5月，斯特罗贝克博士担任制药公司Trevena, Inc.的首席商务官。在加入Trevena之前，斯特罗贝克博士曾在制药公司葛兰素史克、风险投资公司SR One Limited和EuclidSR Partners，L.P担任管理职务。斯特罗贝克博士目前是Horse Power For Life的董事会成员，该公司是一家非营利组织，致力于提高被诊断患有癌症的人的生活质量，他自2012年以来一直担任该职位。斯特罗贝克博士于1993年在圣劳伦斯大学获得生物学学士学位，1999年在辛辛那提大学获得药理学和生物物理学博士学位，并于2001年在宾夕法尼亚大学医学院完成了心血管基因调控方面的博士后研究。
Mark Strobeck,has served as a member of Windtree Therapeutics, Inc. Board since June 2023 and also serves as a member of the Audit and Compensation Committees. Dr. Strobeck has also served as the President and CEO, and as a member of the board of directors, of Rockwell Medical, Inc., a biopharmaceutical company, since July 2022. Dr, Strobeck previously served as Managing Director of Aquilo Partners, LP, a life sciences investment bank, from May 2021 to June 2022. He previously served as Executive Vice President and Chief Operating Officer of Assertio Holdings, Inc., a pharmaceutical company, from May 2020 to December 2020. Prior to that, Dr. Strobeck was Executive Vice President and Chief Operating Officer of Zyla Life Sciences, a pharmaceutical company, from September 2015 through its merger with Assertio Holdings, Inc. in May 2020, and previously served as Zyla's Chief Business Officer from January 2014 to September 2015. Before his employment at Zyla, he served as Zyla's advisor from June 2012 to December 2013. From January 2012 to December 2013, he served as President and Chief Executive Officer and a director of Corridor Pharmaceuticals, Inc., a pharmaceuticals company, which was acquired by AstraZeneca plc in 2014. From December 2010 to October 2011, Dr. Strobeck served as Chief Business Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur in the fourth quarter of 2011. From June 2010 to November 2010 and October 2011 to January 2012, Dr. Strobeck worked as a consultant. From January 2008 to May 2010, Dr. Strobeck served as Chief Business Officer of Trevena, Inc., a pharmaceutical company. Prior to joining Trevena, Dr. Strobeck held management roles at GlaxoSmithKline plc, a pharmaceuticals company, and venture capital firms SR One Limited and EuclidSR Partners, L.P. Dr. Strobeck currently serves on the board of directors of Horse Power For Life, a nonprofit organization dedicated to improving the quality of life for individuals diagnosed with cancer, a position he has held since 2012. Dr. Strobeck received his B.S. in Biology from St. Lawrence University in 1993 and his Ph.D. in Pharmacology and Biophysics from the University of Cincinnati in 1999 and completed his post-doctoral fellowship in Cardiovascular Gene Regulation at the University of Pennsylvania School of Medicine in 2001. - Mark Strobeck自2023年6月起担任Windtree Therapeutics, Inc.董事会成员，并担任审计和薪酬委员会成员。自2022年7月起，斯特罗贝克博士还担任生物制药公司Rockwell Medical, Inc.的总裁兼首席执行官和董事会成员。斯特罗贝克博士曾于2021年5月至2022年6月担任生命科学投资银行Aquilo Partners，LP的董事总经理。他曾于2020年5月至2020年12月担任制药公司Assertio Holdings, Inc.执行副总裁兼首席运营官。在此之前，斯特罗贝克博士于2015年9月与Assertio Holdings公司于2020年5月合并后担任制药公司Zyla Life Sciences的执行副总裁兼首席运营官，并曾于2014年1月至2015年9月担任Zyla的首席商务官。在受雇于Zyla之前，他曾在2012年6月至2013年12月期间担任Zyla的顾问。2012年1月至2013年12月，他担任Corridor Pharmaceuticals，Inc.的总裁兼首席执行官和董事。Corridor Pharmaceuticals，Inc.是一家制药公司，于2014年被阿斯利康收购。2010年12月至2011年10月，斯特罗贝克博士担任Topaz Pharmaceuticals Inc.的首席商务官，这是一家专业制药公司，于2011年第四季度被赛诺菲巴斯德收购。2010年6月至2010年11月和2011年10月至2012年1月，斯特罗贝克博士担任顾问。2008年1月至2010年5月，斯特罗贝克博士担任制药公司Trevena, Inc.的首席商务官。在加入Trevena之前，斯特罗贝克博士曾在制药公司葛兰素史克、风险投资公司SR One Limited和EuclidSR Partners，L.P担任管理职务。斯特罗贝克博士目前是Horse Power For Life的董事会成员，该公司是一家非营利组织，致力于提高被诊断患有癌症的人的生活质量，他自2012年以来一直担任该职位。斯特罗贝克博士于1993年在圣劳伦斯大学获得生物学学士学位，1999年在辛辛那提大学获得药理学和生物物理学博士学位，并于2001年在宾夕法尼亚大学医学院完成了心血管基因调控方面的博士后研究。
- Mark Strobeck,has served as a member of Windtree Therapeutics, Inc. Board since June 2023 and also serves as a member of the Audit and Compensation Committees. Dr. Strobeck has also served as the President and CEO, and as a member of the board of directors, of Rockwell Medical, Inc., a biopharmaceutical company, since July 2022. Dr, Strobeck previously served as Managing Director of Aquilo Partners, LP, a life sciences investment bank, from May 2021 to June 2022. He previously served as Executive Vice President and Chief Operating Officer of Assertio Holdings, Inc., a pharmaceutical company, from May 2020 to December 2020. Prior to that, Dr. Strobeck was Executive Vice President and Chief Operating Officer of Zyla Life Sciences, a pharmaceutical company, from September 2015 through its merger with Assertio Holdings, Inc. in May 2020, and previously served as Zyla's Chief Business Officer from January 2014 to September 2015. Before his employment at Zyla, he served as Zyla's advisor from June 2012 to December 2013. From January 2012 to December 2013, he served as President and Chief Executive Officer and a director of Corridor Pharmaceuticals, Inc., a pharmaceuticals company, which was acquired by AstraZeneca plc in 2014. From December 2010 to October 2011, Dr. Strobeck served as Chief Business Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur in the fourth quarter of 2011. From June 2010 to November 2010 and October 2011 to January 2012, Dr. Strobeck worked as a consultant. From January 2008 to May 2010, Dr. Strobeck served as Chief Business Officer of Trevena, Inc., a pharmaceutical company. Prior to joining Trevena, Dr. Strobeck held management roles at GlaxoSmithKline plc, a pharmaceuticals company, and venture capital firms SR One Limited and EuclidSR Partners, L.P. Dr. Strobeck currently serves on the board of directors of Horse Power For Life, a nonprofit organization dedicated to improving the quality of life for individuals diagnosed with cancer, a position he has held since 2012. Dr. Strobeck received his B.S. in Biology from St. Lawrence University in 1993 and his Ph.D. in Pharmacology and Biophysics from the University of Cincinnati in 1999 and completed his post-doctoral fellowship in Cardiovascular Gene Regulation at the University of Pennsylvania School of Medicine in 2001.
- Jed A. Latkin
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Saundra Pelletier
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Andrew Kucharchuk
-
Andrew Kucharchuk，自2024年10月起担任Cero Therapeutics Holdings，Inc.的首席财务官，自2024年4月起担任Chain Bridge I，Inc.的首席财务官。此前，他自2023年5月至2024年6月担任Theralink Technologies，Inc.（“Theralink”）的首席财务官，并于2020年6月至2021年12月担任Theralink的代理首席财务官。他自2020年6月起担任Theralink董事会成员。Kucharchuk先生还分别于2019年11月至2020年6月以及2006年11月至2019年10月在Theralink收购OBMP之前担任OncBioMune，Inc.（“OBMP”）的首席执行官和首席财务官。Kucharchuk先生于2020年7月至2022年9月期间担任Adhera Therapeutics，Inc.的董事长兼首席执行官，并于2022年10月至2023年10月期间担任其首席运营官。Kucharchuk先生毕业于路易斯安那州立大学和杜兰大学弗里曼商学院，在那里他获得了MBA学位。
Andrew Kucharchuk has served as Chief Financial Officer since inception. He has served as CFO of Range I since June 2025. Mr. Kucharchuk also currently serves as Chief Financial Officer of Cero Therapeutics, Inc (Nasdaq: CERO). Previoly, he served as the Chief Financial Officer of Theralink Technologies, Inc. ("Theralink") (OTCMKTS: THER) from May 2023 until May 2024, and also served as President and Chief Financial Officer of Theralink from February 2016 until June 2020 and as Acting Chief Financial Officer of Theralink from June 2020 to September 2020. He served on the Board of Directors of Theralink from June 2020 until June 2024. In addition, Mr. Kucharchuk served as Chief Executive Officer and Chief Financial Officer of OncBioMune, Inc. ("OBMP") prior to Theralink's acquisition of OBMP. Mr. Kucharchuk also served as the Chairman and Chief Operating Officer Adhera Therapeutics, Inc. (OTCMKTS: ATRX) from July 2020 until September 2022 and its Chief Operations Officer from October 2022 to September 2024. Mr. Kucharchuk is a graduate of Louisiana State University and Tulane University's Freeman School of Biness, where he earned an MBA with a Finance Concentration. - Andrew Kucharchuk，自2024年10月起担任Cero Therapeutics Holdings，Inc.的首席财务官，自2024年4月起担任Chain Bridge I，Inc.的首席财务官。此前，他自2023年5月至2024年6月担任Theralink Technologies，Inc.（“Theralink”）的首席财务官，并于2020年6月至2021年12月担任Theralink的代理首席财务官。他自2020年6月起担任Theralink董事会成员。Kucharchuk先生还分别于2019年11月至2020年6月以及2006年11月至2019年10月在Theralink收购OBMP之前担任OncBioMune，Inc.（“OBMP”）的首席执行官和首席财务官。Kucharchuk先生于2020年7月至2022年9月期间担任Adhera Therapeutics，Inc.的董事长兼首席执行官，并于2022年10月至2023年10月期间担任其首席运营官。Kucharchuk先生毕业于路易斯安那州立大学和杜兰大学弗里曼商学院，在那里他获得了MBA学位。
- Andrew Kucharchuk has served as Chief Financial Officer since inception. He has served as CFO of Range I since June 2025. Mr. Kucharchuk also currently serves as Chief Financial Officer of Cero Therapeutics, Inc (Nasdaq: CERO). Previoly, he served as the Chief Financial Officer of Theralink Technologies, Inc. ("Theralink") (OTCMKTS: THER) from May 2023 until May 2024, and also served as President and Chief Financial Officer of Theralink from February 2016 until June 2020 and as Acting Chief Financial Officer of Theralink from June 2020 to September 2020. He served on the Board of Directors of Theralink from June 2020 until June 2024. In addition, Mr. Kucharchuk served as Chief Executive Officer and Chief Financial Officer of OncBioMune, Inc. ("OBMP") prior to Theralink's acquisition of OBMP. Mr. Kucharchuk also served as the Chairman and Chief Operating Officer Adhera Therapeutics, Inc. (OTCMKTS: ATRX) from July 2020 until September 2022 and its Chief Operations Officer from October 2022 to September 2024. Mr. Kucharchuk is a graduate of Louisiana State University and Tulane University's Freeman School of Biness, where he earned an MBA with a Finance Concentration.
高管简历
中英对照 | 中文 | 英文- Steven G. Simonson
Steven G. Simonson，自2017年4月起担任Windtree Therapeutics, Inc.高级副总裁兼首席医疗官，曾于2014年10月至2017年4月担任Windtree Therapeutics, Inc.高级副总裁兼首席开发官，并于2014年5月加入公司后担任Windtree Therapeutics, Inc.临床开发副总裁。他在AstraZeneca Pharmaceuticals任职15年，主要在肺、心血管和重症监护治疗领域担任医疗和临床领导职务。他参与或领导了几项成功的IND和NDA申请。在接下来的两年里，他担任Agennix, Inc.（主要专注于肿瘤学和败血症的生物制药公司）的临床开发副总裁。他也是Covance（生物制药开发服务公司）分子开发集团的执行董事，在那里他将自己的经验应用于中小型生物技术和制药公司的临床开发项目。Simonson博士完成了内科培训，随后在杜克大学医学中心（Duke University Medical Center）获得肺病和重症监护医学奖学金。随后，他在杜克大学麻醉科和医学系（包括肺科和重症医学系）担任了几个教职。他是美国胸科医师学会会员，也是多篇同行评审出版物、摘要、海报和章节的作者或合著者。他获得了威斯康星医学院的医学学位，以及杜克大学医学院的生物计量学健康科学硕士学位。
Steven G. Simonson,has served as Windtree Therapeutics, Inc. Senior Vice President and Chief Medical Officer, or CMO, since April 2017, having previously served as Windtree Therapeutics, Inc. Senior Vice President and Chief Development Officer from October 2014 to April 2017, and Windtree Therapeutics, Inc. Vice President, Clinical Development, upon joining the Company in May of 2014. Dr. Simonson spent 15 years at AstraZeneca Pharmaceuticals in areas of medical and clinical leadership primarily in the pulmonary, cardiovascular, and critical care therapeutic areas. He has been involved in or led several successful IND and NDA filings. He spent the next two years as Vice President of Clinical Development at Agennix, Inc., a biopharmaceutical company primarily focused in oncology and sepsis. Dr. Simonson was also an Executive Director in the Molecule Development Group at Covance, a biopharmaceutical development services company, where he applied his experience to developing clinical development programs for small and mid-size biotech and pharmaceutical companies. Dr. Simonson completed training in internal medicine followed by a fellowship in pulmonary and critical care medicine at Duke University Medical Center. He then held several faculty appointments at Duke in the departments of Anesthesiology and Medicine, including the divisions of Pulmonary and Critical Care Medicine. He is a Fellow of the American College of Chest Physicians, and author or co-author of multiple peer reviewed publications, abstracts, posters and chapters. Dr. Simonson received his medical degree from the Medical College of Wisconsin, and his Master of Health Sciences degree in Biometry from the Duke University School of Medicine.- Steven G. Simonson，自2017年4月起担任Windtree Therapeutics, Inc.高级副总裁兼首席医疗官，曾于2014年10月至2017年4月担任Windtree Therapeutics, Inc.高级副总裁兼首席开发官，并于2014年5月加入公司后担任Windtree Therapeutics, Inc.临床开发副总裁。他在AstraZeneca Pharmaceuticals任职15年，主要在肺、心血管和重症监护治疗领域担任医疗和临床领导职务。他参与或领导了几项成功的IND和NDA申请。在接下来的两年里，他担任Agennix, Inc.（主要专注于肿瘤学和败血症的生物制药公司）的临床开发副总裁。他也是Covance（生物制药开发服务公司）分子开发集团的执行董事，在那里他将自己的经验应用于中小型生物技术和制药公司的临床开发项目。Simonson博士完成了内科培训，随后在杜克大学医学中心（Duke University Medical Center）获得肺病和重症监护医学奖学金。随后，他在杜克大学麻醉科和医学系（包括肺科和重症医学系）担任了几个教职。他是美国胸科医师学会会员，也是多篇同行评审出版物、摘要、海报和章节的作者或合著者。他获得了威斯康星医学院的医学学位，以及杜克大学医学院的生物计量学健康科学硕士学位。
- Steven G. Simonson,has served as Windtree Therapeutics, Inc. Senior Vice President and Chief Medical Officer, or CMO, since April 2017, having previously served as Windtree Therapeutics, Inc. Senior Vice President and Chief Development Officer from October 2014 to April 2017, and Windtree Therapeutics, Inc. Vice President, Clinical Development, upon joining the Company in May of 2014. Dr. Simonson spent 15 years at AstraZeneca Pharmaceuticals in areas of medical and clinical leadership primarily in the pulmonary, cardiovascular, and critical care therapeutic areas. He has been involved in or led several successful IND and NDA filings. He spent the next two years as Vice President of Clinical Development at Agennix, Inc., a biopharmaceutical company primarily focused in oncology and sepsis. Dr. Simonson was also an Executive Director in the Molecule Development Group at Covance, a biopharmaceutical development services company, where he applied his experience to developing clinical development programs for small and mid-size biotech and pharmaceutical companies. Dr. Simonson completed training in internal medicine followed by a fellowship in pulmonary and critical care medicine at Duke University Medical Center. He then held several faculty appointments at Duke in the departments of Anesthesiology and Medicine, including the divisions of Pulmonary and Critical Care Medicine. He is a Fellow of the American College of Chest Physicians, and author or co-author of multiple peer reviewed publications, abstracts, posters and chapters. Dr. Simonson received his medical degree from the Medical College of Wisconsin, and his Master of Health Sciences degree in Biometry from the Duke University School of Medicine.
- Eric Curtis
Eric Curtis自2020年3月起担任我们的高级副总裁兼首席运营官。在加入我们之前，他最近于2018年6月至2019年11月担任Centurion Biopharma的首席执行官兼总裁，Centurion Biopharma是一家专注于生物制药研究与开发的公司，也是Cytrx Corporation的私人子公司。Curtis先生主要负责公司的公司战略、管道开发计划和业务开发。在担任该职位之前，他于2018年2月至2020年3月担任专注于肿瘤学的生物制药公司Cytrx Corporation的总裁兼首席运营官。Curtis先生的职责包括公司战略、管道开发和投资者关系。在此之前，Curtis先生是Curtis Biopharm Consulting的负责人，他领导他的咨询业务与多家生物制药公司的首席执行官合作，以完善其公司的战略产品开发，商业化有效性和集中资源（从2016年到2018年2月）。在此之前，Curtis先生于2014年至2016年担任生物制药公司Aegerion Pharmaceuticals的美国商业总裁。他领导我们的商业组织，代表全球业务发展的商业，并是投资者关系战略和执行的商业领导。
Eric Curtis,has served as Windtree Therapeutics, Inc. Senior Vice President and Chief Operating Officer since March 2020. Prior to joining Windtree Therapeutics, Inc. , he served as Chief Executive Officer and President of Centurion BioPharma, a biopharmaceutical research and development focused company and a private subsidiary of CytRx Corporation, from June 2018 to November 2019. Mr. Curtis was primarily responsible for the company's corporate strategy, pipeline development plan and business development. Prior to that role, he was President and Chief Operating Officer of CytRx Corporation, a biopharmaceutical company focused in oncology, from February 2018 to March 2020. Mr. Curtis' responsibilities included corporate strategy, pipeline development and investor relations. Before that, Mr. Curtis was principal of Curtis Biopharm Consulting where he led his consulting business to work with the chief executive officers of several biopharmaceutical companies on refining their company's strategic product development, commercialization effectiveness and focusing resources from 2016 to February 2018. Before that, Mr. Curtis served as President, US Commercial of Aegerion Pharmaceuticals, a biopharmaceutical company from 2014 to 2016. He led the commercial organization for US, represented commercial for global business development and was the lead of commercial for investor relations strategy and execution. Mr. Curtis earned his MBA from Pennsylvania State University, and his B.S. in Business and Psychology from the University of Pittsburgh.- Eric Curtis自2020年3月起担任我们的高级副总裁兼首席运营官。在加入我们之前，他最近于2018年6月至2019年11月担任Centurion Biopharma的首席执行官兼总裁，Centurion Biopharma是一家专注于生物制药研究与开发的公司，也是Cytrx Corporation的私人子公司。Curtis先生主要负责公司的公司战略、管道开发计划和业务开发。在担任该职位之前，他于2018年2月至2020年3月担任专注于肿瘤学的生物制药公司Cytrx Corporation的总裁兼首席运营官。Curtis先生的职责包括公司战略、管道开发和投资者关系。在此之前，Curtis先生是Curtis Biopharm Consulting的负责人，他领导他的咨询业务与多家生物制药公司的首席执行官合作，以完善其公司的战略产品开发，商业化有效性和集中资源（从2016年到2018年2月）。在此之前，Curtis先生于2014年至2016年担任生物制药公司Aegerion Pharmaceuticals的美国商业总裁。他领导我们的商业组织，代表全球业务发展的商业，并是投资者关系战略和执行的商业领导。
- Eric Curtis,has served as Windtree Therapeutics, Inc. Senior Vice President and Chief Operating Officer since March 2020. Prior to joining Windtree Therapeutics, Inc. , he served as Chief Executive Officer and President of Centurion BioPharma, a biopharmaceutical research and development focused company and a private subsidiary of CytRx Corporation, from June 2018 to November 2019. Mr. Curtis was primarily responsible for the company's corporate strategy, pipeline development plan and business development. Prior to that role, he was President and Chief Operating Officer of CytRx Corporation, a biopharmaceutical company focused in oncology, from February 2018 to March 2020. Mr. Curtis' responsibilities included corporate strategy, pipeline development and investor relations. Before that, Mr. Curtis was principal of Curtis Biopharm Consulting where he led his consulting business to work with the chief executive officers of several biopharmaceutical companies on refining their company's strategic product development, commercialization effectiveness and focusing resources from 2016 to February 2018. Before that, Mr. Curtis served as President, US Commercial of Aegerion Pharmaceuticals, a biopharmaceutical company from 2014 to 2016. He led the commercial organization for US, represented commercial for global business development and was the lead of commercial for investor relations strategy and execution. Mr. Curtis earned his MBA from Pennsylvania State University, and his B.S. in Business and Psychology from the University of Pittsburgh.
- Jed A. Latkin
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介